Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-05-08
Disclosure Type: Single Sales/Supply Contract (Amendment)
💡 3-Second Summary
Samsung Biologics has increased its biopharmaceutical contract manufacturing organization (CMO) contract with global pharmaceutical company Eli Lilly (Eli Lilly Kinsale Limited) from approximately KRW 327.8 billion to KRW 584.1 billion, a financial adjustment representing 50.14% of its baseline annual revenue.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Counterparty: Eli Lilly Kinsale Limited
- Contract Type: Biopharmaceutical Contract Manufacturing Organization (CMO) Contract
- Contract Amount (Amended):
- (Before) KRW 327,826,300,620 (USD 268,842,300)
- (After) KRW 584,071,016,620 (USD 478,982,300)
- Net Increase: Increased by USD 210,140,000 (Approx. KRW 256.2B) at the request of the client.
- Exchange Rate: Calculated by applying the initial exchange rate of 1,219.40 KRW/USD from the original disclosure date (March 28, 2022).
- Proportion to Annual Revenue (Amended):
- (Before) 28.14% → (After) 50.14%
- The baseline annual revenue (KRW 1,164,776,873,641) is based on the company’s 2020 consolidated financial statements from the initial filing.
- Contract Period: December 20, 2019 – December 31, 2029 (Subject to change upon mutual agreement).
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Impact on Fundamental Changes: This disclosure outlines a material upward revision of a contract total by more than KRW 256.2 billion at the client’s request. By increasing the cumulative contract value with Eli Lilly to KRW 584.1 billion through late 2029, this update expands the long-term revenue pipeline, which may generate a positive potential impact on financial metrics over the contract duration.
- Risks and Red Flags for Investors: While the contract value has been adjusted upward, the disclosure simply notes the reason as a “change in contract amount at the request of the client.” It does not specify any concrete reasons for the adjustment, such as shifts in product demand or unit price changes, meaning investors should avoid speculative conclusions. Additionally, because the monetary figures remain anchored to the historical 2022 exchange rate of 1,219.40 KRW/USD, actual reported revenue could fluctuate depending on spot exchange rates during billing periods. Furthermore, as the contract end date is subject to change based on mutual agreement, the timeline for quarterly revenue recognition may remain fluid.
📝 Editor’s Comment (by K-STOCK Editor)
A large-scale upward adjustment in the hundreds of billions of won has been finalized, pushing the contract’s proportion relative to baseline revenue past the 50% threshold. Although the filing formally states that the amount was amended simply at the request of the client, market participants may focus heavily on the fact that the cumulative size of this long-term deal with a global Big Pharma partner has expanded significantly. However, since variables related to execution timelines and exchange rate settlements could still influence the final outcomes, investors may want to maintain a balanced perspective on how this adjustment will translate into long-term potential impacts.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
